Compare UBSI & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UBSI | DFTX |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.9B |
| IPO Year | 1994 | 2020 |
| Metric | UBSI | DFTX |
|---|---|---|
| Price | $48.59 | $34.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | $51.67 | ★ $72.78 |
| AVG Volume (30 Days) | 822.4K | ★ 1.7M |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $311,957,000.00 | N/A |
| Revenue This Year | $4.32 | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | $17.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $34.68 | $14.62 |
| 52 Week High | $50.47 | $49.70 |
| Indicator | UBSI | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.92 | 47.64 |
| Support Level | $47.69 | $32.43 |
| Resistance Level | $49.62 | $38.59 |
| Average True Range (ATR) | 1.01 | 2.11 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 49.58 | 46.71 |
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which offers a full range-of-products and services through various delivery channels. Included among the banking products and services offered are the acceptance of deposits in checking, savings, time, and money market accounts; the making and servicing of personal, credit card, commercial, and floor plan loans; and the making of construction and real estate loans, as well as the origination and sale of residential mortgages in the secondary market. Also offered are trust and brokerage services, safe deposit boxes, and wire transfers.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.